EP2823043A1 — High concentration alpha-glucosidase compositions for the treatment of pompe disease
Assigned to Amicus Therapeutics Inc · Expires 2015-01-14 · 11y expired
What this patent protects
The present application provides for compositions comprising high concentrations of acid a-glucosidase in combination with an active site-specific chaperone for the acid alpha-glucosidase, and methods for treating Pompe disease in a subject in need thereof, that includes a method…
USPTO Abstract
The present application provides for compositions comprising high concentrations of acid a-glucosidase in combination with an active site-specific chaperone for the acid alpha-glucosidase, and methods for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an acid alpha-glucosidase enzyme formulation.
Drugs covered by this patent
- Zavesca (MIGLUSTAT) · AstraZeneca
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.